What is OncoPep?
OncoPep, Inc. operates at the intersection of immunology and oncology, focusing on the development of therapeutic cancer vaccines. The company utilizes an exclusively licensed technology platform that combines proprietary peptides with specialized adjuvants to prime the patient's immune system to recognize and eliminate malignant cells. This targeted approach represents a significant shift from traditional systemic treatments, offering a more precise mechanism for disease management. With a robust history of financing, including Series A through Series D rounds, the company has demonstrated a consistent ability to translate complex biological research into scalable clinical assets. Its market position is bolstered by a strategic focus on disease-specific peptide combinations, which are designed to enhance efficacy while minimizing off-target effects, thereby addressing critical unmet needs in the oncology market.
How much funding has OncoPep raised?
OncoPep has raised a total of $28.4M across 5 funding rounds:
Angel/Seed
$4.5M
Series A
$2.5M
Private Equity
$3.5M
Series B
$6.9M
Series D
$11M
Angel/Seed (2011): $4.5M, investors not publicly disclosed
Series A (2012): $2.5M led by NewSpring Health Capital
Private Equity (2014): $3.5M supported by NewSpring Health Capital
Series B (2014): $6.9M featuring The Leukemia & Lymphoma Society
Series D (2021): $11M backed by KUKJE Pharma, Tera Science, CrystalBioScience, and SX Company
Key Investors in OncoPep
NewSpring Health Capital
NewSpring partners with companies in dynamic industries to catalyze new growth. Partnering with management teams to help develop their businesses into market leaders, NewSpring identifies opportunities and builds relationships using through it's network of industry leaders.
The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society is at the forefront of the fight to cure cancer. We are the largest nonprofit dedicated to creating a world without blood cancers. Since 1949, weve invested nearly $1.3 billion in groundbreaking research, pioneering many of todays most innovative approaches.
KUKJE Pharma
KUKJE PHARM CO.,LTD specializes in the production and distribution of a wide range of pharmaceutical products, including antibiotics, antifungal agents, corticosteroids, and various other medications.
What's next for OncoPep?
With the successful closure of its most recent financing round, OncoPep is well-positioned to accelerate its clinical development pipeline and expand its research infrastructure. The influx of capital will likely be directed toward advancing its lead therapeutic candidates through rigorous clinical trials and optimizing its proprietary peptide manufacturing processes. As the company transitions into a more mature phase of its lifecycle, stakeholders will be monitoring the progression of its vaccine candidates and the potential for strategic partnerships with larger pharmaceutical entities. The focus remains on achieving key regulatory milestones and validating the long-term clinical utility of its immunotherapeutic platform, which could redefine standard-of-care protocols for various cancer indications.
See full OncoPep company page
